Search

Displaying results 8861 - 8870 of 9313 in total
  1. Drug

    Pegcrisantaspase

    go.drugbank.com/drugs/DB16281
    Investigational

    Following Hypersensitivity to Pegaspargase (Oncaspar)).

  2. Drug

    Acloproxalap

    go.drugbank.com/drugs/DB21553
    Investigational

    Acloproxalap is under investigation in clinical trial NCT06685692 (A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1)).

  3. Drug

    FP0011

    go.drugbank.com/drugs/DB05090
    Experimental

    It acts on the presynaptic regulation of glutamate and shows strong neuroprotective properties.

  4. Drug

    Alvocidib

    go.drugbank.com/drugs/DB03496
    Investigational

    Alvocidib is a synthetic flavonoid based on an extract from an Indian plant for the potential treatment of cancer.

  5. Drug

    VH3739937

    go.drugbank.com/drugs/DB25287
    Investigational

    VH3739937 is under investigation in clinical trial NCT06533280 (VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE

  6. Drug

    Thiostrepton

    go.drugbank.com/drugs/DB11467
    InvestigationalVet approved

    Thiostrepton is a natural product of the ribosomally synthesized and post-translationally modified peptide class.

  7. Drug

    Ulixertinib

    go.drugbank.com/drugs/DB13930
    Investigational

    It is currently in clinical trials for the treatment of a wide range of tumors.

  8. Drug

    Ontuxizumab

    go.drugbank.com/drugs/DB16270
    Investigational

    Ontuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1).

  9. Drug

    Mevidalen

    go.drugbank.com/drugs/DB19034
    Investigational

    Mevidalen is under investigation in clinical trial NCT03305809 (A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or

  10. Drug

    IDM-1

    go.drugbank.com/drugs/DB05292
    Experimental

    IDM-1 is IDM’s most advanced antibody-based Cell drug for the treatment of cancer.